[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yongjun Chen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,35,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":28,"completionDateStruct":30,"leadSponsor":32,"locationsCount":4},"100616913","impact-of-vascular-resection-on-survival-and-postoperative-outcomes-in-patients-with-hilar-cholangiocarcinoma-a-retrospective-study-100616913",false,"NCT07311798","Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study","Inclusion Criteria:\n\n* Patients who underwent surgical treatment at the Department of Hepatobiliary and Pancreatic Surgery of our hospital between January 2010 and December 2024, including those with or without concomitant vascular resection.\n* Pathologically confirmed diagnosis of hilar cholangiocarcinoma after surgery.\n* Complete clinical and follow-up data available for outcome analysis.\n\nExclusion Criteria:\n\n* Patients with distant metastasis or who underwent only palliative or exploratory surgery.\n* Patients diagnosed preoperatively or intraoperatively with other types of biliary malignancies not located at the hilar region.\n* Patients with incomplete medical records or missing key clinical or follow-up data.","ALL",{"count":17,"type":18},300,"ESTIMATED","OBSERVATIONAL","Hilar cholangiocarcinoma is a highly aggressive malignancy, and surgical resection remains the only potentially curative treatment. Due to the frequent involvement of major vascular structures, vascular resection is increasingly performed to achieve negative surgical margins; however, its impact on survival and postoperative outcomes remains controversial. This retrospective study aims to evaluate the association between vascular resection and clinical outcomes, including survival and postoperative outcomes, in patients with hilar cholangiocarcinoma undergoing curative-intent surgery.",[22],"Cholangiocarcinoma, Hilar","NOT_YET_RECRUITING","2025-12-29",{"date":26,"type":27},"2025-12-31","ACTUAL",{"date":29,"type":18},"2025-12",{"date":31,"type":18},"2026-02",{"name":33,"class":34},"Yongjun Chen","OTHER",{"id":36,"slug":37,"hasResults":11,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":4,"eligibilityCriteria":41,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":42,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":43,"conditions":44,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100604441","volume-restricted-resection-for-perihilar-cholangiocarcinoma-100604441","NCT07149558","Volume-Restricted Resection for Perihilar Cholangiocarcinoma","Volume-Restricted Liver Resections for Perihilar Cholangiocarcinoma With Insufficient Future Liver Remnant Volume: A Prospective, Multicenter, Real-World Study","Inclusion Criteria:\n\n* Patients with pathologically confirmed hilar cholangiocarcinoma, or those with a high index of clinical suspicion for hilar bile duct malignancy despite the lack of histological confirmation.\n* Patients who are able to understand and cooperate with this study.\n* Patients who are able to provide and sign the written informed consent form before undergoing any screening procedures related to the study.\n\nExclusion Criteria:\n\n* Patients with preoperatively or intraoperatively confirmed distant metastasis, including peritoneal dissemination, distant lymph node metastasis, hepatic or other organ metastasis.\n* Patients who underwent palliative surgery only.",{"count":17,"type":18},"The goal of this observational study is to learn about the safety and long-term outcomes of volume-restricted liver resection in patients with perihilar cholangiocarcinoma (pCCA) who have an insufficient future liver remnant (FLR). The main question it aims to answer is:\n\nDoes volume-restricted liver resection improve surgical safety and long-term survival compared with standard treatment in pCCA patients with insufficient FLR?\n\nParticipants with insufficient FLR who undergo volume-restricted liver resection or receive non-surgical treatment as part of their routine medical care will be followed for survival, postoperative complications, and other clinical outcomes. Data from patients with sufficient FLR undergoing standard radical resection will also be collected for comparison.",[22],"2025-08-29",{"date":47,"type":27},"2025-09-02",{"date":49,"type":18},"2026-01",{"date":51,"type":18},"2034-01",{"name":33,"class":34},{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":15,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100603363","phase-2-a-single-arm-multicenter-exploratory-study-of-adebrelimab-combined-with-apatinib-and-systemic-chemotherapy-for-initially-unresectable-biliary-tract-cancer-100603363","NCT07135544","A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","Inclusion Criteria:\n\n\\- 1. Pathological or histological diagnosis of malignant tumor of the biliary tract; 2. Patients who are classified as TxNx and TxNxM1 according to the UICC\u002FAJCC TNM staging system (9th edition, 2024), and who, based on the judgment of the research team, meet the criteria for newly diagnosed incurable cases or are not suitable for surgery; 3. Age: 18-80 years old; 4. Expected survival period \\> 3 months; 5. Both genders are eligible; 6. ECOG PS score of 0 or 1; 7. No severe complications, such as hypertension, coronary heart disease, and history of mental illness, no severe allergy history; non-pregnant and non-lactating; 8. The patient's organ and hematological system functions meet the following requirements:\n\n1. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n2. Platelet count ≥ 75 × 10\\^9\u002FL;\n3. Hemoglobin ≥ 90 g\u002FL;\n4. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN);\n5. Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN;\n6. Albumin ≥ 3 g\u002FdL\n7. Creatinine ≤ 1.5 x ULN 9. Patients can understand and sign the informed consent form to participate in the trial study; good compliance.\n\n10\\. Newly diagnosed patients, who have not undergone any local or systemic treatment for the tumor in the past and have undergone radical resection surgery for biliary cancer, and whose disease recurs 2 years after the surgery can be included; 11. Patients with potential fertility should use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment and within 1 month after the end of the study treatment; and the serum or urine HCG test must be negative within 72 hours before the study enrollment, and must be non-lactating.\n\nExclusion Criteria:\n\n* 1\\. Patients who received immune checkpoint inhibitors before enrollment, or those who directly received another stimulatory or co-inhibitory T-cell receptor (such as CTLA-4, CD137); 2. Patients who used any other investigational drug within 4 weeks before enrollment; 3. Patients with any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy); children with asthma who have completely recovered after adulthood and do not require any intervention can be included, but patients requiring bronchodilator drug intervention cannot be included; 4. Congenital or acquired immune deficiencies, such as infection with human immunodeficiency virus (HIV), active hepatitis B (HBV DNA \\> 500 IU\u002Fml), hepatitis C (positive hepatitis C antibody, HCV-RNA above the detection limit of the analytical method), or co-infection of hepatitis B and hepatitis C; 5. Serious infections occurred within 4 weeks before the first administration (such as intravenous infusion of antibiotics, antifungal or antiviral drugs), or unexplained fever \\> 38.5°C during screening or before the first administration; 6. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 7. Having an uncontrolled mental disorder; 8. Concurrently having severe and\u002For uncontrollable diseases that may affect the participation in the study, such as unstable angina pectoris, myocardial infarction within 6 months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, poorly controlled diabetes, excessive activity, uncontrollable infection after insufficient biliary drainage (such as tumor blocking the bile duct); 9. Other cancers that occurred in the past (within the past 5 years) or simultaneously, excluding non-melanoma skin cancer and carcinoma in situ; 10. History of allergy or hypersensitivity to any study drug or any monoclonal antibody; 11. Unable or unwilling to sign the informed consent form.","18 Years","80 Years",{"count":62,"type":18},37,"INTERVENTIONAL",[65],"PHASE2","This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.",[68,69],"Biliary Tract Cancer","Biliary Tract Cancer (CCA)",[71],"Adebrelimab","RECRUITING","2025-08-20",{"date":75,"type":27},"2025-08-22",{"date":77,"type":27},"2025-08-14",{"date":79,"type":18},"2028-12-30",{"name":33,"class":34},1,""]